GenVec (GNVC) versus Regulus Therapeutics (RGLS) Head-To-Head Comparison
GenVec (NASDAQ: GNVC) and Regulus Therapeutics (NASDAQ:RGLS) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation.
Insider and Institutional Ownership
6.2% of GenVec shares are owned by institutional investors. Comparatively, 53.7% of Regulus Therapeutics shares are owned by institutional investors. 8.1% of GenVec shares are owned by insiders. Comparatively, 4.8% of Regulus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This table compares GenVec and Regulus Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Regulus Therapeutics||$70,000.00||1,407.92||-$81.83 million||($0.75)||-1.26|
GenVec has higher earnings, but lower revenue than Regulus Therapeutics. Regulus Therapeutics is trading at a lower price-to-earnings ratio than GenVec, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of current ratings for GenVec and Regulus Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Regulus Therapeutics has a consensus target price of $2.38, indicating a potential upside of 150.53%.
This table compares GenVec and Regulus Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Regulus Therapeutics beats GenVec on 7 of the 9 factors compared between the two stocks.
GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company’s development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company’s lead product candidate is CGF166. The Company’s vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.
About Regulus Therapeutics
Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company’s Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.
Receive News & Ratings for GenVec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenVec and related companies with MarketBeat.com's FREE daily email newsletter.